Intranasal Drug Delivery Devices Market Outlook
The global intranasal drug delivery devices market was valued at USD 4,061.4 Mn in 2020 and is expected to reach USD 6,601.7 Mn by 2028, expanding at a CAGR of 6.5% during the forecast period. Nasal administration has been used for therapeutic purposes for centuries. The respiratory tract is a primary contact area for the environment and it represents a gateway for potential treatments and infectious particles such as viruses & bacteria. Intranasal administration is a non-invasive drug route of administration, widely used for the local treatment of nasal polyposis or rhinitis.
In order to obtain effective and safe intranasal pharmaceutical products, a large number of strategies is applied to overcome nasal release barriers. In the design of a nasal product, three main cooperative entities must be considered: the administration device, the drug, and the delivery carrier. Nasal drug administration has been used as an alternative route for the systemic availability of drugs restricted to intravenous administration.
This is attributed to the large surface area, porous endothelial membrane, high total blood flow, avoidance of first-pass metabolism, and ready accessibility. The nasal administration of drugs, including numerous compounds, peptide and protein drugs, for systemic medication has been widely investigated in recent years. Drugs are cleared rapidly from the nasal cavity after intranasal administration, resulting in rapid systemic drug absorption.
Scope of Intranasal Drug Delivery Devices Market Report
The report on the global Intranasal Drug Delivery Devices Market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Report Title
|
Intranasal Drug Delivery Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Product (Powder Delivery Device, Liquid Delivery Device, Pressurized Metered-dose Inhalers, and Others), Dosage (Unit-dose and Multi-dose) Application (Respiratory Disorders, Neurological Disorder, Vaccination, Pain Management and Others), End-user (Personal Use, Hospitals/Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered
|
Teleflex Incorporated, AptarGroup, Inc., Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Vectura Group plc, Recipharm AB, H&T Presspart Manufacturing Ltd, Nemera Development S.A., OptiNose Inc, and Others.
|
Intranasal Drug Delivery Devices Market Dynamics
Increasing Prevalence of Chronic Disease
Demand for nasal sprays is growing, owing to the increasing prevalence of chronic diseases, such as cardiovascular diseases (CVDs), nasal congestion, chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease (COPD), and diabetes. This is expected to propel the intranasal drug delivery devices market during the forecast period.
Topical forms of medical therapy represent an attractive alternative for the administration of drugs into the paranasal sinuses and nasal cavity. The increasing incidence of chronic diseases is projected to contribute to the expansion of the intranasal drug delivery devices market over the coming years.
Introduction of Off-patent Drugs for Respiratory Care to Reconcile the Supply of MDIs and DPIs
The expiration of the patent for branded inhaled drugs and increasing pressure on the healthcare budget are leading to the development of generic inhaled drugs. As the cost of treating asthma and COPD decreases, awareness and the adoption of MDI & DPI are likely to increase among patients. Companies are focusing on the development of low-cost drugs to provide cost-effective treatment.
For instance, in February 2019, the US Food and Drug Administration (FDA) approved Mylan’s generic version of Advair Diskus of GlaxoSmithKline. The generic drug (Wixela Inhub) is intended for the treatment of asthma and COPD patients and was launched at a lower price than the brand. Additionally, increased patient awareness of the benefits of using MDI and DPI are expected to propel the market over the coming years.
Restraints
Rising Complications associated with the overuse of nasal sprays
Sprays are easy to access for patients, hence most people mistakenly presume that nasal sprays are safe to use and are unaware of the potential addiction or possible side effects. Rhinitis Medicamentosa (RM) refers to the nasal inflammation caused by the use of medications. It is common for patients who regularly use nasal sprays to abuse the drug.
Continuous use of nasal sprays leads to down-regulation of the receptors on the blood vessel in the nose, which methat the number of receptors decreases, and when the user stops taking the drug, a rebound effect of nasal inflammation occurs. Atrophy of the nasal mucosa is a common drawback associated with rhinitis medicamentosa. This includes scars of the nose coating, which causes symptoms such as bleeding, dry nose, and irritation.
Difficulty in delivering the drug to the olfactory region of the human nasal cavity
Drug delivery devices have been found to play an important role in ensuring that all of the drugs are delivered to the target site in the nasal cavity. It is difficult to accurately deliver the drug to the olfactory region of the human nasal cavity, as this region is located high in the nasal cavity, above the upper concha. This area is exposed to a low volume of air entering the nasal cavity and leads to low doses of the drug reaching the olfactory region. This in turn, is expected to impede the growth of the intranasal drug delivery devices market during the forecast period.
Opportunity
Increasing R&D Activities
Innovative strategic approaches to design efficient nasal delivery systems for specific drugs are currently in various stages of research and development. These include the design of barriers that prevent the degradation of drugs by mucosal enzymes, sophisticated devices for targeted drug delivery to the brain, new and improved nasal delivery technologies, and the modulation of physicochemical properties of the vectors. This in turn, is anticipated to provide various lucrative growth opportunities during the forecast period.
Intranasal Drug Delivery Devices Market Segmental Outlook
The intranasal drug delivery devices market is segmented into products, dosage, applications, end-users, distribution channels, and regions.
On the basis of products, the global intranasal drug delivery devices market is segmented into powder delivery device, liquid delivery device, pressurized metered-dose inhalers, and others. The liquid delivery device segment held a significant market share and is anticipated to grow in the coming years. Liquid delivery devices are considered convenient, particularly for topical indications where humidification counteracts the dryness and crusting often accompanying chronic nasal diseases.
Based on dosage, the global intranasal drug delivery devices market is segmented into unit-dose and multi-dose. The unit-dose segment held a significant market share and is anticipated to grow in the coming years. A unit-dose device is for single-use, pre-filled, already-assembled, disposable products such as IMITREX (sumatriptan nasal spray) and NARCAN (naloxone nasal spray). It is ideal for urgent treatments.
In terms of applications, the global intranasal drug delivery devices market is segmented into respiratory disorders, neurological disorders, vaccination, pain management, and others. The increasing prevalence of respiratory disorders such as asthma and COPD among people is expected to propel the global intranasal drug delivery devices market in the coming years.
On the basis of end-users, the global intranasal drug delivery devices market is segmented into personal use, hospitals/clinics, and others. The personal use segment is expected to hold a significant market share during the forecast period, owing to increasing patient preference for self-administrated drugs and the growing usage of nasal sprays and powders that are easily administered by patients. Furthermore, the self-administration of drugs in home care settings helps patients save money and time, which in turn, brings down healthcare costs incurred by the patient.
Based on distribution channels, the global intranasal drug delivery devices market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held a significant market share and is anticipated to grow in the coming years, owing to increasing focus on positive medical outcomes, patient awareness, and self-administration.
Intranasal Drug Delivery Devices Market Regional Outlook
On the basis of regions, the global intranasal drug delivery devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing government (U.S. FDA) approval for the use of the intranasal drug delivery devices such as nasal sprays and nasal powder.
The market in Europe is expected to grow at a rapid pace during the forecast period, due to the presence of large number of players in the region. The market in Asia Pacific is projected to hold considerable market share during the forecast period, owing to increasing R&D activities in countries such as China.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Intranasal Drug Delivery Devices market
- Historical, Current and Projected Market Size in terms of Value and Volume
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Intranasal Drug Delivery Devices Market Performance
Segments
By Product
- Powder Delivery Device
- Liquid Delivery Device
- Pressurized Metered-dose Inhalers
- Others
By Dosage
By Application
- Respiratory Disorders
- Neurological Disorder
- Vaccination
- Pain Management
- Others
By End-user
- Personal Use
- Hospitals/Clinics
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- Teleflex Incorporated
- AptarGroup, Inc.
- Johnson & Johnson
- BD
- Teva Pharmaceutical Industries Ltd
- Vectura Group plc
- Recipharm AB
- H&T Presspart Manufacturing Ltd
- Nemera Development S.A.
- OptiNose Inc
- Others
Competitive Landscape
- Top players in the market include Johnson & Johnson, BD, Teva Pharmaceutical Industries Ltd, Nemera Development S.A., AptarGroup, Inc., and Recipharm AB Limited these companies are considered as key manufacturers of piezoelectric element based on their revenue, product offerings, regional presence, and supply chain management system.
- The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Intranasal Drug Delivery Devices market.